AR074347A1 - Composicion solida para liberacion controlada de agentes activos ionizables con solubilidad acuosa deficiente a ph bajo y sus metodos de uso - Google Patents

Composicion solida para liberacion controlada de agentes activos ionizables con solubilidad acuosa deficiente a ph bajo y sus metodos de uso

Info

Publication number
AR074347A1
AR074347A1 ARP090104410A ARP090104410A AR074347A1 AR 074347 A1 AR074347 A1 AR 074347A1 AR P090104410 A ARP090104410 A AR P090104410A AR P090104410 A ARP090104410 A AR P090104410A AR 074347 A1 AR074347 A1 AR 074347A1
Authority
AR
Argentina
Prior art keywords
active agent
solid composition
group
composition according
controlled release
Prior art date
Application number
ARP090104410A
Other languages
English (en)
Original Assignee
Portola Pharm Inc
Patheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41466672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074347(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Portola Pharm Inc, Patheon Inc filed Critical Portola Pharm Inc
Publication of AR074347A1 publication Critical patent/AR074347A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica sólida para la liberación controlada de un agente activo en el tracto gastrointestinal que comprende: (a) al menos un agente activo ácido con una solubilidad de menos de alrededor de 0,3 mg/ml en una solución acuosa a un pH de - cómo máximo - alrededor de la pKa del agente activo ácido a una temperatura de alrededor de 37°C, o una de sus sales farmacéuticamente aceptables; (b) al menos un polímero hidrófilo y (c) al menos un alcalinizador; en donde la composición reduce la evacuación del estómago; y provee al menos alrededor del 70% de liberación del agente activo durante un período de tiempo de entre alrededor de 7 y alrededor de 12 horas después de la administración oral. Reivindicación 6: La composición sólida de acuerdo con la reivindicación 1, en donde el agente activo tiene la fórmula (1) en donde R1 se selecciona del grupo que consiste e H, halógeno, -OH, alquilo C1-10 y alquilamino C1-6; y X se selecciona del grupo que consiste de F e I. Reivindicación 7: La composición sólida de acuerdo con la reivindicación 1, en donde el agente activo es sal [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2H-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilurea potásica. Reivindicación 13: La composición sólida de acuerdo con la reivindicación 1, en donde el polímero hidrófilo se selecciona del grupo que consiste de un éter de celulosa, óxido de polietileno, ácido acrílico, y combinaciones de ellos. Reivindicación 16: La composición sólida de acuerdo con la reivindicación 1, en donde el alcalinizador se selecciona del grupo que consiste de carbonato de calcio, óxido de magnesio, bicarbonato de sodio y arginina y sales farmacéuticamente aceptables de los mismos. Reivindicación 29: El método de acuerdo con la reivindicación 28, en donde el trastorno cardiovascular es trombosis.
ARP090104410A 2008-11-14 2009-11-13 Composicion solida para liberacion controlada de agentes activos ionizables con solubilidad acuosa deficiente a ph bajo y sus metodos de uso AR074347A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11494108P 2008-11-14 2008-11-14
US11500808P 2008-11-14 2008-11-14

Publications (1)

Publication Number Publication Date
AR074347A1 true AR074347A1 (es) 2011-01-12

Family

ID=41466672

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104410A AR074347A1 (es) 2008-11-14 2009-11-13 Composicion solida para liberacion controlada de agentes activos ionizables con solubilidad acuosa deficiente a ph bajo y sus metodos de uso

Country Status (13)

Country Link
US (2) US20100151019A1 (es)
EP (1) EP2376065A2 (es)
JP (1) JP2012508773A (es)
KR (1) KR20110097829A (es)
CN (1) CN102271663A (es)
AR (1) AR074347A1 (es)
AU (1) AU2009313867A1 (es)
BR (1) BRPI0921049A2 (es)
CA (1) CA2743639A1 (es)
CL (1) CL2009002073A1 (es)
RU (1) RU2011123377A (es)
TW (1) TW201022253A (es)
WO (1) WO2010057036A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
CN102123701B (zh) 2008-05-09 2013-03-27 格吕伦塔尔有限公司 使用喷雾冻凝步骤制备中间粉末制剂以及最终固体剂型的方法
NZ596667A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
AU2011209940B2 (en) 2010-02-01 2015-08-20 Mikrobex Inc. Bacteriotherapy for clostridium difficile colitis
ES2606227T3 (es) 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
KR20130137627A (ko) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 음이온성 중합체를 포함하는 내변조성 투여형
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012072824A1 (en) * 2010-12-03 2012-06-07 Novartis Ag Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
NO2736497T3 (es) 2011-07-29 2018-01-20
EP2760821B1 (en) * 2011-09-02 2017-10-11 Novartis AG Choline salt of an anti-inflammatory substituted cyclobutenedione compound
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2870012A1 (en) 2012-05-11 2013-11-14 Grunenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2719376B1 (en) * 2012-10-12 2015-03-04 Omya International AG Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
BR112016031000B1 (pt) * 2014-07-01 2022-01-25 Probi USA, Inc. Forma de dosagem em camadas e método para fazer a mesma
EP3206673A1 (en) * 2014-10-17 2017-08-23 Fidia Farmaceutici S.p.A. Dermal therapeutic system with high adhesivity
JP6532153B2 (ja) * 2015-01-30 2019-06-19 ライオン株式会社 内服用錠剤
EP3253376A1 (en) 2015-02-03 2017-12-13 Grünenthal GmbH Tamper-resistant dosage form comprising a polyethylene glycol graft copolymer
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10905726B2 (en) * 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) * 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN110869007B (zh) * 2017-06-23 2022-10-14 太阳医药高级研究有限公司 防滥用的口服固体剂型
JP7158189B2 (ja) * 2018-07-11 2022-10-21 東洋電装株式会社 スロットルグリップ装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
MX2007012642A (es) * 2005-04-11 2008-01-11 Abbott Lab Composiciones farmaceuticas que tienen perfiles mejorados de disolucion para farmacos poco solubles.
ATE540034T1 (de) * 2005-11-03 2012-01-15 Portola Pharm Inc Ä4-(6-halo-7-substituierte-2,4-dioxo-1,4-dihydr - 2h-chinazolin-3-yl)-phenylü-5-chloro-thiophen-2 yl-sulfonylharnstoffe und relevante formen und verfahren
MX2009011755A (es) * 2007-05-02 2010-02-12 Portola Pharm Inc Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.

Also Published As

Publication number Publication date
US20130172374A1 (en) 2013-07-04
TW201022253A (en) 2010-06-16
CL2009002073A1 (es) 2010-12-24
EP2376065A2 (en) 2011-10-19
CN102271663A (zh) 2011-12-07
JP2012508773A (ja) 2012-04-12
AU2009313867A1 (en) 2011-06-30
BRPI0921049A2 (pt) 2017-03-28
CA2743639A1 (en) 2010-05-20
RU2011123377A (ru) 2012-12-20
WO2010057036A2 (en) 2010-05-20
KR20110097829A (ko) 2011-08-31
US20100151019A1 (en) 2010-06-17
WO2010057036A3 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
AR074347A1 (es) Composicion solida para liberacion controlada de agentes activos ionizables con solubilidad acuosa deficiente a ph bajo y sus metodos de uso
ES2555989T3 (es) Procedimiento para la síntesis del ácido 2,5-furanodicarboxílico
ES2656901T3 (es) Una formulación estabilizada de pemetrexed
PE20080741A1 (es) Formulaciones parenterales de metilnaltrexona y sus sales
JP2015506989A5 (es)
AR086190A1 (es) Preparacion de gadobutrol de alta pureza
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
AR068598A1 (es) Composicion de cuidado oral de fluoruro que forma espuma
NZ602321A (en) Compound and use for reducing uric acid comprising 2-(3-(2,6-Dimethylbenzyloxy)-4-methylphenyl)acetic acid
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
JP2012527488A5 (es)
AR081870A1 (es) Composicion farmaceutica que comprende un derivado de amida o sal farmaceuticamente aceptable del mismo
ES2605495T3 (es) Solución de atomoxetina
AR077436A1 (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables.
EA201171399A1 (ru) Способ и композиция для улучшения всасывания лекарственных средств
AR065529A1 (es) Forma de dosificacion que comprende 1-{6-((3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi)-3-piridinil}-2-pirrolidinona , metodo para producirla su uso para preparar un medicamento y disolucion o suspension correspondiente
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
RS51920B (en) PROCEDURE FOR THE SYNTHESIS OF IVABRADINE AND ITS ADDITIONAL SALTS WITH PHARMACEUTICALLY ACCEPTABLE ACID
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales
NI201100119A (es) Composición de liberación pulsatil de sildenafil y proceso para prepararla.
CO6160302A2 (es) Formulaciones farmaceuticas
HRP20211761T1 (hr) Dvokomponentna kompozicija koja sadrži acetilsalicilnu kiselinu
AR067048A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure